Eli Lilly's big Summer 2025 update
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
We take a look at some exciting upcoming presentations by Eli Lilly about it's old and new GLP1 receptor agonists.
Novo Nordisk and Eli Lilly dominate the market for GLP1 Receptor Agonists.
After the war on compounders seems to be mostly over (though there are still some compounders around), the companies are still in heavy competition to build the best, most effective GLP1s.
While we normally focus on news that has already broken here at GLP1.Guide, we thought it was worth mentioning that Eli Lilly plans to announce a raft of updates on their GLP1s that are under development, so for those who want to get ahead of the news, it's worth watching:
Eli Lilly is presenting their updates at the American Diabetes Association's (ADA) 85th Scientific Sessions.
GLP1 Receptor Agonists were first and foremost a tool for helping with type 2 diabetes, so this is a fitting venue for presenting updates, even though many of the focus around GLP1s lately have been towards weight loss. Now that supply issues have been ameliorated (and people who need the medication the most are able to access them), few seem to be against touting the weight loss benefits of the drugs.
The event is taking place from June 20th to 23rd in Chicago, at the McCormick convention center.
Tirzepatide is the most effective and comprises the most popular GLP1 brand names that Eli Lilly makes available: Mounjaro and Zepbound.
Tirzepatide was recently confirmed to be more effective than semaglutide in a head to head study:
GLP1.Guide Staff
So what left is there to announce? More trials.
Here are the presentations that will happen related to Tirzepatide:
You can read up on the SURMOUNT-1 trial here:
Get the full breakdown of the SURMOUNT-5 trial here:
Get the data on the SURPASS-SWITCH trial here:
Retatrutide is one of the most exciting GLP1s in development right now, with amazing results being discussed on the internet for those who are in trials and/or obtaining it via other means.
GLP1.Guide Staff
Here are the presentations that are about Retatrutide:
This presentation is sure to be an eye-opening one – normally studies on mouse models are to be somewhat discounted/not taken seriously given that effects may not transfer over to humans, but we already know that GLP1s are massively effective in humans.
Having a head to head comparison of three of the most popular GLP1s that we know to be effective in humans on a mouse model might be a quicker way to find out differences that will carry over to humans (and just how more effective Retatrutide can be expected to be.
Orgorglipron is a orally administered GLP1 pill that Eli Lilly has been working on which looks to be a huge improvement over some competitors (like Rybelsus):
GLP1.Guide Staff
Here are the presentations coming up on Orforglipron:
The title of this presentation is quite modest, but we're going to assume the answer to the question is a "yes" and the presenter will be telling us why.
A much lesser known drug under development by Eli Lily is Bimagrumab, an compliment to other GLP1s (like Semaglutide).
Here is the presentation on Bimagrumab:
While somewhat overblown, the worries about loss of lean mass (generally, muscle) while losing weight with GLP1s (and in general) have been a large concern for most people. Rumors swirling around GLP1s have been that people would suddenly lose muscle, but this is a natural effective
That said, being able to prevent the loss of lean mass is certainly a step forward, and that's one of the things that Bimagrumab can help with when combined with a GLP1 (in this case Semaglutide, which is developed by Novo Nordisk).
Another somewhat unknown GLP1 is Eloralinitide, which serves to try and improve the outcomes of those who are already on a GLP1 (similar to Bimagrumab).
Here is the presentation on Eloralinitide:
GI problems are the most pronounced negative side effects that have been associated with GLP1s so far, and anything that could be added to prevent them would be a huge boon for GLP1 safety.
Unfortunately, this research seems to be in mouse models so it will be a while until the results can be proven in humans, but it will be great to hear of progress.
This group of updates are sure to be very positive for the GLP1 ecosystem and should shed light on how different drugs under development are faring and whether they are indeed better that what is available now on the market.
At present, the common sense interpretation of the current state of things seems to be:
Tirzepatide > Semaglutide > Liraglutide > Exenatide
It seems like most of these new drugs will sit firmly on the left side of the above relation – meaning that more, even more effective GLP1s are on the horizon, a cause for celebration.
Finally, a research clinical trial that directly explores the difference between Semaglutide and Tirzepatide for Obesity.
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.